---
id: out-hcm-briefing-20260410-round1-working-en
type: output
output_kind: briefing
language: en
topic: hcm
question: "Based on the current HCM seed corpus, what is the first usable internal view of feline hypertrophic cardiomyopathy across recognition, endpoints, genotype pressure, remodeling, and treatment?"
source_ids: [src-hcm-001, src-hcm-004, src-hcm-006, src-hcm-007, src-hcm-008, src-hcm-009, src-hcm-010, src-hcm-012, src-hcm-013, src-hcm-015, src-hcm-020, src-hcm-024]
generated_at: 2026-04-10
verification_status: compiled
decision_grade: no
language_qa_status: light_checked
language_qa_notes: "2026-04-22 checked for wording drift; working-English layer only, not decision-grade diagnostic or treatment guidance."
owner: codex
status: draft
evidence_policy:
  quoted_fact: []
  source_supported_conclusion: []
  llm_inference: []
---

# Internal Briefing: Feline HCM Round 1

## User Question

Based on the current HCM seed corpus, what is the first usable internal view of feline hypertrophic cardiomyopathy across recognition, endpoints, genotype pressure, remodeling, and treatment?

## Executive Answer

Current evidence supports treating feline HCM as a `structure-first cardiomyopathy module`, not as a biomarker-first, mutation-only, or treatment-first disease story.

The strongest current architectural conclusion is that feline HCM should be organized around:

- structural phenotype confirmation
- bounded screening augmentation
- stratified genotype pressure
- remodeling beneath visible phenotype
- treatment reality constrained by evidence skepticism

The current corpus also says four operational things clearly.

First, `echocardiography` and gross morphometry currently lead recognition. They should stay above biomarkers in the operational hierarchy.

Second, the biomarker branch is now more separable than before:

- `troponin I` fits best as injury or severity pressure
- `NT-proBNP` fits best as a severe-disease flag, not as a reliable mild-disease screen

Third, genetics should not be flattened into mutation present versus absent. The current corpus already supports `dosage-sensitive severity` and `age-related penetrance` as meaningful parts of the HCM map.

Fourth, treatment is real but still overclaim-sensitive. The safest current frame is `bounded management + selective targeted frontier`, while keeping prescribing behavior separate from evidence strength.

This file is the working-English briefing. It should not be mistaken for a bilingual or Chinese-facing summary. Paired `-en` and `-zh` files, if created later, are derivative language-facing outputs built on top of this working layer.

## Evidence-Backed Points

### quoted_fact

- Broad feline cardiomyopathy and HCM review material supports structure-led phenotype framing rather than one-test diagnosis.
- An echocardiographic assessment paper reports spontaneously occurring feline HCM as structurally heterogeneous rather than one uniform hypertrophy pattern.
- A troponin-I study reports higher cTnI in moderate-to-severe HCM and still higher values with active congestive heart failure.
- An NT-proBNP screening study reports useful severe-HCM signal but failure to screen mild-to-moderate or equivocal HCM in the studied colony.
- A genetics-focused clinical study reports stronger severity and penetrance pressure in homozygous MYBPC3-mutant cats than in heterozygous cats.
- A remodeling-focused paper supports cardiomyocyte-initiated and macrophage-driven remodeling language rather than treating hypertrophy as the whole disease.
- An anatomopathological staging paper supports end-stage HCM as a deeper remodeled phenotype rather than just more wall thickening.
- A treatment-skepticism paper explicitly questions whether feline HCM treatment is based more on science or faith.

### source_supported_conclusion

- The top recognition branch for HCM should remain `structure-first`, with biomarkers and AI-like tools below it.
- `Troponin I` and `NT-proBNP` now belong in different sublayers and should not be presented as interchangeable HCM markers.
- `Genotype pressure` is already meaningful enough to shape severity interpretation, but it should deepen phenotype reading rather than replace structural confirmation.
- `Remodeling` should be treated as a real mechanism branch beneath phenotype, not as a minor pathology appendix.
- `End-stage HCM` should be modeled as a remodeled phenotype involving fibrosis and broader structural change, not as simple continuation of hypertrophy alone.
- The current treatment branch is strong enough for internal layered briefing, but not strong enough for a flat final intervention ranking.
- HCM should stay visible inside a broader feline cardiomyopathy frame rather than absorbing non-HCM cardiomyopathies into its core spine.

### llm_inference

- The most reusable first-wave HCM output architecture is likely:
  1. recognition and workup
  2. endpoint hierarchy
  3. genotype-severity pressure
  4. phenotype-to-remodeling bridge
  5. treatment-evidence boundary
- HCM may become one of the clearest modules where `treatment skepticism` is structurally important rather than merely cautionary language.

## Uncertainty / Limits

- This briefing is built from first-round extraction, not full-text line-by-line review of every HCM paper in the seed set.
- The current HCM seed corpus contains 24 mapped sources, and all 24 paper cards now have round-1 deep extraction coverage; this briefing still is not full-text line-by-line review or decision-grade guidance.
- Treatment evidence remains less settled than recognition and phenotype architecture.
- AI and frontier-marker work remain present but are not strong enough for first-line authority.
- Regulatory or product-route interpretation remains thin and should not be inferred from this briefing.
- This briefing should not be used as a submission-grade or guideline-grade decision document.

## Suggested Write-Back Targets

- `topics/hcm/index.md`
- `topics/hcm/mechanism-overview.md`
- `topics/hcm/endpoint-handbook.md`
- `topics/hcm/risk-and-recognition.md`
- `topics/hcm/translation-brief.md`
- `topics/hcm/synthesis-index.md`

## Promotion Judgment

- repeated? `yes`
- structurally clarifying? `yes`
- evidence-safe enough for this layer? `partly`
- smallest durable home: `topic update + synthesis update + briefing output; stay chat-only for any flat treatment ranking`

### Reason

- what is repeating:
  HCM questions keep converging on structure-first recognition, biomarker separation, genotype pressure, remodeling depth, and treatment-boundary caution
- what becomes clearer:
  this briefing compresses HCM into a reusable architecture instead of a loose pile of review, biomarker, genetics, and pathology notes
- what is still too thin, if anything:
  treatment hierarchy and frontier-marker ranking are still thinner than phenotype and workup architecture

### Decision

- promote selected structure only; hold stronger treatment-ranking language

## Source IDs

- src-hcm-001
- src-hcm-004
- src-hcm-006
- src-hcm-007
- src-hcm-008
- src-hcm-009
- src-hcm-010
- src-hcm-012
- src-hcm-013
- src-hcm-015
- src-hcm-020
- src-hcm-024
